Early administration of the drug Fosdenopterin/rcPMP improves the chances of survival of infants with MoCD type A and promotes the development of brain functions. The drug fosdenopterin/rcPMP ...
The drug fosdenopterin/rcPMP considerably improves the chances of survival and developmental progress in infants with molybdenum cofactor deficiency (MoCD type A), a ...
PALO ALTO, Calif. and SOLANA BEACH, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic ...
The drug, fosdenopterin, is a treatment for molybdenum cofactor deficiency (MoCD) type A. Babies born with this disease experience a rapid progression of neurological problems including seizures, ...
These data represent the first comprehensive body of clinical research in the only approved treatment for MoCD Type A patients, as well as the most abundant findings on the natural progression of the ...
SAN FRANCISCO, Sept. 29, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Origin Biosciences today announced the US Food and Drug Administration (FDA) has accepted its New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results